Azeb Yirga1, Taofik Oyekunle1,2, Lauren E Howard1,2, Amanda M De Hoedt1, Matthew R Cooperberg3, Christopher J Kane4, William J Aronson5,6, Martha K Terris7,8, Christopher L Amling9, Emanuela Taioli10, Jay H Fowke11, Zachary Klaanssen1, Stephen J Freedland12, Adriana C Vidal13. 1. Surgery Section, Durham VA Health Care System, Durham, NC, USA. 2. Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA. 3. Department of Urology, Diller Family Comprehensive Cancer Center, UCSF Helen, San Francisco, CA, USA. 4. Urology Department, University of California San Diego Health System, San Diego, CA, USA. 5. Urology Section, Department of Surgery, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 6. Department of Urology, UCLA School of Medicine, Los Angeles, CA, USA. 7. Section of Urology, Veterans Affairs Medical Center, Augusta, GA, USA. 8. Department of Surgery, Section of Urology, Medical College of Georgia, Augusta, GA, USA. 9. Department of Urology, Oregon Health and Science University Hospital, Portland, OR, USA. 10. Institute for Translational Epidemiology and Tisch Cancer Institute, Icahn School of Medicine At Mount Sinai, New York, NY, USA. 11. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA. 12. Center for Integrated Research On Cancer and Lifestyle, Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, 8631 West 3rd Street Suite 430W, Los Angeles, CA, 90048, USA. 13. Center for Integrated Research On Cancer and Lifestyle, Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, 8631 West 3rd Street Suite 430W, Los Angeles, CA, 90048, USA. Adriana.Vidal@cshs.org.
Abstract
PURPOSE: Circulating inflammatory markers may predict prostate cancer (PC) outcomes. For example, a recent study showed that higher peripheral blood monocyte counts were associated with aggressive PC in Asian men undergoing radical prostatectomy (RP). Herein, we investigated whether peripheral monocyte count can predict long-term PC outcomes after RP in black and white men. METHODS: We retrospectively reviewed data on 2345 men undergoing RP from 2000 to 2017 at eight Veterans Affairs hospitals. Data on monocyte count within 6 and 12 months prior to surgery were collected. The study outcomes were biochemical recurrence (BCR), castration-resistant PC (CRPC), metastasis, all-cause mortality (ACM), and PC-specific morality (PCSM). Cox-proportional hazard models were used to assess the associations between pre-operative monocyte count and the above-mentioned outcomes accounting for confounders. RESULTS: Of 2345 RP patients, 972 (41%) were black and 1373 (59%) were white men. In multivariable analyses, we found no associations between monocyte count and BCR among all men (HR: 1.36, 95%CI 0.90-2.07) or when analyses were stratified by race (HR: 1.30, 95%CI 0.69-2.46, in black men; HR:1.33, 95%CI 0.76-02.33, in white men). Likewise, no overall or race-specific associations were found between monocyte count and CRPC, metastases, ACM, and PCSM, all p ≥ 0.15. Results were similar for monocyte count measured at 12 months prior to RP. CONCLUSION: In black and white PC patients undergoing RP, peripheral monocyte count was not associated with long-term PC outcomes. Contrary to what was found in Asian populations, monocyte count was not associated with PC outcomes in this study.
PURPOSE: Circulating inflammatory markers may predict prostate cancer (PC) outcomes. For example, a recent study showed that higher peripheral blood monocyte counts were associated with aggressive PC in Asian men undergoing radical prostatectomy (RP). Herein, we investigated whether peripheral monocyte count can predict long-term PC outcomes after RP in black and white men. METHODS: We retrospectively reviewed data on 2345 men undergoing RP from 2000 to 2017 at eight Veterans Affairs hospitals. Data on monocyte count within 6 and 12 months prior to surgery were collected. The study outcomes were biochemical recurrence (BCR), castration-resistant PC (CRPC), metastasis, all-cause mortality (ACM), and PC-specific morality (PCSM). Cox-proportional hazard models were used to assess the associations between pre-operative monocyte count and the above-mentioned outcomes accounting for confounders. RESULTS: Of 2345 RP patients, 972 (41%) were black and 1373 (59%) were white men. In multivariable analyses, we found no associations between monocyte count and BCR among all men (HR: 1.36, 95%CI 0.90-2.07) or when analyses were stratified by race (HR: 1.30, 95%CI 0.69-2.46, in black men; HR:1.33, 95%CI 0.76-02.33, in white men). Likewise, no overall or race-specific associations were found between monocyte count and CRPC, metastases, ACM, and PCSM, all p ≥ 0.15. Results were similar for monocyte count measured at 12 months prior to RP. CONCLUSION: In black and white PC patients undergoing RP, peripheral monocyte count was not associated with long-term PC outcomes. Contrary to what was found in Asian populations, monocyte count was not associated with PC outcomes in this study.
Authors: Adriana C Vidal; Lauren E Howard; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Stephen J Freedland Journal: Clin Cancer Res Date: 2014-12-17 Impact factor: 12.531
Authors: Adriana C Vidal; Lauren E Howard; Amanda de Hoedt; Matthew R Cooperberg; Christopher J Kane; William J Aronson; Martha K Terris; Christopher L Amling; Emanuela Taioli; Jay H Fowke; Stephen J Freedland Journal: Cancer Causes Control Date: 2018-04-17 Impact factor: 2.506
Authors: Adriana C Vidal; Zinan Chen; Lauren E Howard; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Emanuela Taioli; Jay H Fowke; Beatrice Knudsen; Charles G Drake; J Curtis Nickel; Stephen J Freedland Journal: Oncotarget Date: 2016-07-18